*Starting doses must be administered in the deltoid muscle.
Due to the difference in median pharmacokinetic profiles between the 2 products (INVEGA® SUSTENNA® and INVEGA® Oral), caution should be exercised when making a direct comparison of their pharmacokinetic properties.
For patients who have never taken oral paliperidone or oral or injectable risperidone, it is recommended to establish tolerability with oral paliperidone or oral risperidone prior to initiating treatment with INVEGA® SUSTENNA®.1
NOTE: Prior to use, establish tolerability with oral paliperidone or oral risperidone. Each injection must be administered only by a healthcare professional. No oral supplementation is needed.
Paliperidone is contraindicated in patients with a known hypersensitivity to either paliperidone, risperidone, or to any excipients of the formulation.
|Missed monthly maintenance dose||Dosing schedule|
|4 to 6 weeks since last injection||Resume regular monthly dosing as soon as possible at patient’s previously stabilized dose, followed by injections at monthly intervals.|
|>6 weeks to 6 months since last injection
*If the patient was stabilized on 234 mg, the first 2 doses should be 156 mg.
|Continue dosing at patient’s previously stabilized dose* by giving:
|>6 months since last injection||Restart dosing with normal starting plan:
|Missed second starting dose||Dosing schedule|
|<4 weeks from first injection||Administer the second starting dose of 156 mg in the deltoid muscle as soon as possible.
|4-7 weeks from first injection||Resume dosing with 2 injections of 156 mg:
|>7 weeks from first injection||Restart dosing with normal initiation plan:
INVEGA® SUSTENNA® has a proven safety and tolerability profile. Explore the data >
References: 1. INVEGA® SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; November 2014. 2. Samtani M, Gopal S, Gassmann-Mayer C, et al. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs. 2011;25(10):929-845.